Cargando…

Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy

SIMPLE SUMMARY: This study contributes to the characterization of CD8+ HLA-DR+ T cell mediated-mechanisms involved in the anti-tumor response in breast cancer patients who respond to neoadyuvant chemotherapy (NACT). Cultures with plasma from responder (R), but not from non-responder (NR), patients i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osuna-Gómez, Rubén, Arqueros, Cristina, Galano, Carla, Mulet, Maria, Zamora, Carlos, Barnadas, Agustí, Vidal, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699550/ https://www.ncbi.nlm.nih.gov/pubmed/34944786 http://dx.doi.org/10.3390/cancers13246167

Ejemplares similares

HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy
por: Saraiva, Diana P., et al.
Publicado: (2018)

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
por: Margeli, Mireia, et al.
Publicado: (2010)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer()()
por: Tibau, Ariadna, et al.
Publicado: (2014)

Functional Change of Effector Tumor-Infiltrating CCR5(+)CD38(+)HLA-DR(+)CD8(+) T Cells in Glioma Microenvironment
por: Chen, Pin-Yuan, et al.
Publicado: (2019)

Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients
por: Escuin, Daniel, et al.
Publicado: (2023)

HLA-DM Interactions with Intermediates in HLA-DR Maturation and a Role for HLA-DM in Stabilizing Empty HLA-DR Molecules
por: Denzin, Lisa K., et al.
Publicado: (1996)

Association of HLA-DR1, HLA-DR13, and HLA-DR16 Polymorphisms with Systemic Lupus Erythematosus: A Meta-Analysis
por: Wang, Tingrui, et al.
Publicado: (2022)

Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
por: Leary, Alexandra, et al.
Publicado: (2020)

Matching for HLA-DR excluding diabetogenic HLA-DR3 and HLA-DR4 predicts insulin independence after pancreatic islet transplantation
por: Ballou, Cassandra, et al.
Publicado: (2023)

HLA-DR polymorphism affects the interaction with CD4
Publicado: (1995)

MicroRNA-1291 Is Associated With Locoregional Metastases in Patients With Early-Stage Breast Cancer
por: Escuin, Daniel, et al.
Publicado: (2020)

Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Liu, Zining, et al.
Publicado: (2021)

Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15
por: Enz, Lukas Simon, et al.
Publicado: (2019)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alba, Emilio, et al.
Publicado: (2016)

Association of HLA-DR3 and HLA-DR15 Polymorphisms with Risk of Systemic Lupus Erythematosus
por: Xue, Ke, et al.
Publicado: (2018)

Intratumoral HLA-DR(−)/CD33(+)/CD11b(+) Myeloid-Derived Suppressor Cells Predict Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Hasnis, Erez, et al.
Publicado: (2020)

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy
por: Jin, Zining, et al.
Publicado: (2015)

Circulating microRNAs in Early Breast Cancer Patients and Its Association With Lymph Node Metastases
por: Escuin, Daniel, et al.
Publicado: (2021)

Estimation of US patients with cancer who may respond to cytotoxic chemotherapy
por: Maldonado, Edward B, et al.
Publicado: (2020)

Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
por: Yao, Liqin, et al.
Publicado: (2022)

Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes
por: Costa-García, Marcel, et al.
Publicado: (2019)

Effects of Neoadjuvant Chemotherapy on Benign Breast Lesions Compared to Cancers: Should an Additional Lesion on Magnetic Resonance Imaging Responding Similar to Cancer after Neoadjuvant Chemotherapy be Viewed with Suspicion?
por: Leddy, Rebecca, et al.
Publicado: (2016)

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
por: Ledys, Fanny, et al.
Publicado: (2018)

A Perspective on the Application of Covalent Organic Frameworks for Detection and Water Treatment
por: Arqueros, Cristina, et al.
Publicado: (2021)

T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP
Publicado: (1989)

Conventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report
por: Kimura, Yutaro, et al.
Publicado: (2017)

Circulating HLA-DR(+)CD4(+) effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis
por: Ahmed, Asma, et al.
Publicado: (2018)

Immune independent crosstalk between lymphoma and myeloid suppressor CD14(+)HLA-DR(low/neg) monocytes mediates chemotherapy resistance
por: Zhang, Zhe (Jenny), et al.
Publicado: (2015)

T cell recognition of self-human histocompatibility leukocyte antigens (HLA)-DR peptides in context of syngeneic HLA-DR molecules
Publicado: (1992)

HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants
Publicado: (1985)

Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature
por: Wu, Jie, et al.
Publicado: (2022)

Avoiding breast cancer surgery in a select cohort of complete responders to neoadjuvant chemotherapy: The long-term outcomes
por: Apte, Anuradha, et al.
Publicado: (2021)

Fibrillary Glomerulonephritis Is Associated With HLA-DR7 and HLA-B35 Antigens
por: Andeen, Nicole K., et al.
Publicado: (2020)

The HLA-DRα Chain Is Modified by Polyubiquitination
por: Lapaque, Nicolas, et al.
Publicado: (2009)

Effect of Selenium on HLA-DR Expression of Thyrocytes
por: Balázs, Csaba, et al.
Publicado: (2012)

HLA-DR Association in Papillary Thyroid Carcinoma
por: Amoli, Mahsa M., et al.
Publicado: (2010)

The curious case of HLA‐DR‐positive APL
por: Devi, Kanta, et al.
Publicado: (2020)

Reverse-SSO hybridization provides an accurate and simple HLA-DR typing--a comparative study with HLA-DR serologic typing.
por: Lee, K. W., et al.
Publicado: (1994)

Haplotypes of the HLA-G 3’ Untranslated Region Respond to Endogenous Factors of HLA-G+ and HLA-G- Cell Lines Differentially
por: Poras, Isabelle, et al.
Publicado: (2017)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_it82am3j3po68i2ampb15fqtop